Intended Use : This product is intended strictly for qualified laboratory researchers
Back Nathan, DM, Schreiber, E, Fogel, H, et al (Feb 1992) 'Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects', Journal Diabetes Care , 15/2, 270-6
These access barriers are part of what led to a rise in interest in compounded alternatives
NCSL Resources on GLP-1 Drugs Prescription Drug Legislation Database Prescription Drug Policy Resource Center The Debate Over Weight-Loss Drugs Diabetes State Mandates and Insulin Copayment Caps The average annual list price of GLP-1s is $12,000 and, according to a Peterson-KFF tracker, most large employer health plans restrict coverage for weight loss
Patients most commonly experience: Nausea Vomiting Diarrhea Constipation Often when beginning a GLP-1 treatment, your doctor may suggest lower doses initially so your body can adjust to the medication